Quite remarkably, both DHCR7 and UBE2C are members of the recent EndoPredict score assay, which provides prognostic information for endocrine-treated ER+/HER2 − breast cancer patients [35,36]. This evidence concerns the gene ESR1 and breast carcinoma.